Ionis insider plans sale of 8,353 shares

Ionis Pharmaceuticals insider plans another stock sale under Rule 144.

Rhea-AI Filing Summary

Ionis Pharmaceuticals insider plans another stock sale under Rule 144. A holder has filed to sell 8,353 shares of Ionis common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $636,626.29. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation.

The notice also lists recent sales in the past three months for the same account holder. Shannon Devers sold 16,777 shares of common stock on 11/25/2025 for gross proceeds of $1,342,160.00, and 44,199 shares on 01/07/2026 for gross proceeds of $3,760,522.76 through Stifel Nicolaus & Company Inc. The filer represents that they are not aware of undisclosed material adverse information about Ionis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Ionis (IONS) Form 144 filing disclose?

The filing discloses an insider’s intent to sell 8,353 shares of Ionis Pharmaceuticals common stock under Rule 144, with an aggregate market value of $636,626.29, to be sold through Morgan Stanley Smith Barney on NASDAQ.

How were the 8,353 Ionis (IONS) shares being sold acquired?

The 8,353 shares of Ionis common stock were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, and the filing identifies the nature of payment as compensation.

What other recent Ionis (IONS) stock sales by this holder are reported?

The notice lists prior sales for the same account holder: 16,777 shares of Ionis common stock sold on 11/25/2025 for $1,342,160.00, and 44,199 shares sold on 01/07/2026 for $3,760,522.76 through Stifel Nicolaus & Company Inc.

Which broker is handling the new Ionis (IONS) Rule 144 sale and where will it trade?

The proposed sale of 8,353 Ionis common shares is listed with Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036, and the securities exchange named is NASDAQ.

What representation does the seller make about Ionis (IONS) information in this filing?

The seller represents that they do not know any material adverse information about the current or prospective operations of Ionis Pharmaceuticals that has not been publicly disclosed.

How many Ionis (IONS) shares are reported outstanding in this notice?

The filing lists 161,137,930 Ionis Pharmaceuticals common shares as the number of shares outstanding in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 06:36 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002037721
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Devers Shannon L.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	8353	636626.29	161137930	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			8353	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shannon Devers 1367 Gazelle Court 2855 GAZELLE COURT Carlsbad CA 92010	Common Stock	11/25/2025	16777	1342160.00
Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	Common Stock	01/07/2026	44199	3760522.76

144: Remarks and Signature

Remarks
Date of Notice	01/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Shannon Devers
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)